SPECT/CT对胰腺癌125I植入术后剂量验证

doi:10.3969/j.issn.1004-583X.2021.12.013

临床荟萃 ›› 2021, Vol. 36 ›› Issue (12): 1118-1122.doi: 10.3969/j.issn.1004-583X.2021.12.013

SPECT/CT对胰腺癌¹²⁵I植入术后剂量验证

吴维霞^1a, 邢明泉^1b, 周志刚²(), 郭言言^1a, 邱晓辉^1a, 李祥周²

1.亳州市人民医院 a.影像中心; b血液内科,安徽亳州 236800
2.郑州大学第一附属医院放射科,河南郑州 4500000

收稿日期:2021-06-21 出版日期:2021-12-20 发布日期:2021-12-24
通讯作者: 周志刚 E-mail:hnzzg126@126.com

Dosimetric Verification of SPECT/CT to ¹²⁵I implantation for Pancreatic Cancer

Wu Weixia^1a, Xing Mingquan^1b, Zhou Zhigang²(), Guo Yanyan^1a, Qiu Xiaohui^1a, Li Xiangzhou²

1a. Imaging Center; b. Department of Hematology, Bozhou People's Hospital, Bozhou 236800, China
2. Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China

Received:2021-06-21 Online:2021-12-20 Published:2021-12-24
Contact: Zhou Zhigang E-mail:hnzzg126@126.com

摘要/Abstract

摘要：

目的探讨SPECT/CT融合显像应用于胰腺癌¹²⁵I粒子植入术后剂量验证的可行性。方法 18例胰腺癌患者行¹²⁵I粒子植入,术后24 h行SPECT/CT显像,并进行同机融合,将SPECT/CT显像的CT图像导入TPS,进行术后剂量验证,得到等剂量曲线分布图,观察肿瘤周边的放射性浓聚程度与等剂量分布曲线的情况,整体评估并记录肿瘤靶区的覆盖率。在TPS上调整所勾画的靶区进行剂量计算,从DVH图中可知所勾画靶区的平均剂量。重复操作,分别计算出对应区域的平均剂量。重复计算取均值。将放射性浓聚区的单位体积内放射性计数值与所接受平均剂量进行相关分析。结果放射性浓聚区单位体积内放射性计数值与所接受平均剂量之间呈正相关(r=0.422, P<0.01),SPECT/CT显像可使¹²⁵I粒子植入术后粒子周围剂量在一定程度上达到可视化。结论 SPECT/CT 融合显像有望成为¹²⁵I放射性粒子植入术后剂量验证的新方法。

关键词: 胰腺癌, SPECT/CT, ¹²⁵I粒子, 剂量分布, TPS

Abstract:

Objective To explore the feasibility of SPECT/CT imaging applied for dose verification after ¹²⁵I radioactive seed implantation in pancreatic cancer. Methods Eighteen patients with pancreatic cancer were implanted with ¹²⁵I seeds, SPECT/CT imaging was implemented in 24 hours after operation, and the hybride image fusion was implemented. CT images of SPECT/CT imaging were imported into TPS to perform post-operative dose verification, and the isodose curve distribution map was acquired. The radioactive concentration degree surrounding the tumor and isodose distribution curve were observed, the coverage of tumor target region was assessed and recorded overall. The delineated target region on TPS was adjusted for dose calculation, and the mean dose of delineated target region was acquired from DVH chart, and repeated operation was implemented. Mean dose of appropriate regions was respectively calculated. Recalculation and obtainment of mean value were implemented. The correlation analysis between the radioactive count value within the unit of radioactive concentration zone and received mean dose was taken. Results Radioactive count per unit volume of radioactive concentration zone was positively correlated to mean dose received (r=0.422, P<0.01). SPECT/CT imaging could visualize surrounding dose of ¹²⁵I radioactive seeds after implantation to a certain extent. Conclusion SPECT/CT fusion imaging is expected to become a new method of dose verification after implantation of ¹²⁵I radioactive seeds.

Key words: pancreatic cancer, SPECT/CT, ¹²⁵I seed, dose distribution, TPS

中图分类号:

R736.7

吴维霞, 邢明泉, 周志刚, 郭言言, 邱晓辉, 李祥周. SPECT/CT对胰腺癌¹²⁵I植入术后剂量验证[J]. 临床荟萃, 2021, 36(12): 1118-1122.

Wu Weixia, Xing Mingquan, Zhou Zhigang, Guo Yanyan, Qiu Xiaohui, Li Xiangzhou. Dosimetric Verification of SPECT/CT to ¹²⁵I implantation for Pancreatic Cancer[J]. Clinical Focus, 2021, 36(12): 1118-1122.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.12.013

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I12/1118

图/表 6

图1 SPECT/CT融合图像

图2 SPECT图像

图3 SPECT图像中勾画放射性活度区

图4 同一层面肿瘤周边的放射性浓聚程度与等剂量曲线分布情況 a.等剂量曲线分布图;b.SPECT/CT融合图像

图5 DVH图

表1 放射性浓聚区的单位体积内γ计数与所接受剂量关系[M(Q)]

项目	活度范围	r值	P值
γ总计数值(Counts)	5673(5277)	0.422	0.0002
剂量(cGy)	23422(19192)

参考文献 17

[1]	Tomoyuki K. Biomarkers for screening of pancreatic cancer: A risk assessment[J]. Int J Cancer, 2019, 145(7):2002-2004 doi: 10.1002/ijc.32387 pmid: 31054166
[2]	张涛, 孙备. 2019年NCCN胰腺癌临床实践指南(V2版)更新解读[J]. 临床外科杂志, 2020, 28(1):8-11.
[3]	叶俊, 杨都江, 李振录, 陆慧敏, 胡伟明. 放射性¹²⁵I粒子植入治疗不可切除胰腺癌的研究进展[J]. 中国普外基础与临床杂志, 2019, 26(11):1378-1384.
[4]	董丽华. 胰腺癌放射治疗专家共识(2020年版)[J]. 中国医学装备, 2020, 17(12):185-190.
[5]	贾鹏飞, 赵辉. 放射性¹²⁵I粒子植入中空器官与实质器官的剂量学研究进展[J]. 山东医药, 2020, 60(23):103-106.
[6]	王延磊, 王政华. CT引导下¹²⁵I粒子植入联合吉西他滨、卡培他滨治疗局部进展期胰腺癌临床疗效观察[J]. 陕西医学杂志, 2020, 49(12):1604-1607.
[7]	黄斯琪, 宁厚法, 崔新江, 等. ¹²⁵I粒子植入术联合化疗治疗72例不可切除晚期胰腺癌临床观察[J]. 中华肿瘤防治杂志, 2020, 27(17):1415-1420.
[8]	吴维霞, 周志刚, 邢明泉. CT引导下¹²⁵I放射性粒子植入术在不可切除胰腺癌治疗中的应用现状及展望[J]. 中华临床医师杂志(电子版), 2018, 12(3):181-184.
[9]	Li J, Xie Q, Wang W, et al. CT-guided implantation of ¹²⁵I seeds (permanent brachytherapy) for metastatic tumors of the hepatic portal system: Effectiveness and safety in 13 patients[J]. Brachytherapy, 2016, 15(2):224-230. doi: 10.1016/j.brachy.2015.11.003 URL
[10]	李小东, 张遵城, 郑广钧, 等. ¹²⁵I粒子植入治疗非小细胞肺癌的剂量学优化研究[J]. 中华核医学与分子影像杂志, 2015, 35(1):36-40.
[11]	杜鹏, 卢伟, 蒋富强, 等. 同轴穿刺植入¹²⁵I粒子治疗局部晚期胰腺头颈部癌的安全性及有效性[J]. 中国介入影像与治疗学, 2020, 17(9):548-551.
[12]	Sutherland JGH, Miksys N, Furutani KM, et al. Metallic artifact mitigation and organ- constrained tissue assignment for Monte Carlo calculations of permanent implant lung brachytherapy[J]. Med Phys, 2014, 41(1):011712. doi: 10.1118/1.4851555 URL
[13]	赵宪芝, 张宏涛, 底学敏, 等. SPECT/CT探测¹²⁵I粒子放射性浓聚处计数与周围剂量的关系[J]. 中华核医学与分子影像杂志, 2017, 37(6):351-354.
[14]	张宏涛, 刘晓丽, 周汝明, 等. SPECT/CT评价前列腺癌粒子植入剂量分布与疗效初探[J]. 中华介入放射学电子杂志, 2019, 7(4):278-282.
[15]	张宏涛, 苏晓华, 梁岩松, 等. 3D打印模板联合CT引导粒子植入治疗前列腺癌一例报告并文献复习[J]. 中华介入放射学电子杂志, 2019, 7(3):197-201.
[16]	刘利军, 郭振山, 胡敏. 应用SPECT与CT融合图像检测¹²⁵I粒子在靶器官中分布情况的价值[J]. 内蒙古医学杂志, 2018, 50(12):1409-1411.
[17]	张宏涛, 刘晓丽, 周汝明, 等. SPECT/CT评价前列腺癌粒子植入剂量分布与疗效初探[J]. 中华介入放射学电子杂志, 2019, 7(4):278-282.

SPECT/CT对胰腺癌¹²⁵I植入术后剂量验证

Dosimetric Verification of SPECT/CT to ¹²⁵I implantation for Pancreatic Cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 6

参考文献 17

相关文章 1

编辑推荐

Metrics

本文评价